Table 1.
Summary of personal payments from Japanese pharmaceutical companies to infectious disease specialists certified by the Japanese Association for Infectious Disease between 2016 and 2019.
| Variables | Number |
|---|---|
| Total | |
| Payment values, $ | 17,784,070 |
| Contracts, n | 21,680 |
| Companies, n | 78 |
| Average per specialist (SD) | |
| Payment values, $ | 16,857 (45,010) |
| Contracts, n | 20.5 (41.6) |
| Companies, n | 5.6 (5.2) |
| Median per specialist (IQR) | |
| Payment values, $ | 3183 (938–11,250) |
| Contracts, n | 6.0 (2.0–19.0) |
| Companies, n | 4.0 (2.0–8.0) |
| Range | |
| Payment values, $ | 31–711,965 |
| Contracts, n | 1.0–538.0 |
| Companies, n | 1.0–29.0 |
| Physicians with specific payments, n (%) | |
| Any payments | 1055 (65.4) |
| Payments > $500 | 930 (57.6) |
| Payments > $1000 | 776 (48.1) |
| Payments > $5000 | 419 (26.0) |
| Payments > $10,000 | 290 (18.0) |
| Payments > $50,000 | 82 (5.1) |
| Payments > $100,000 | 43 (2.7) |
| Gini index | 0.857 |
| Category of payments | |
| Lecturing | |
| Payment value, $ (%) | 14,607,478 (82.1) |
| Contracts, n (%) | 18,078 (83.1) |
| Consulting | |
| Payment value, $ (%) | 1,981,003 (11.1) |
| Contracts, n (%) | 2122 (9.8) |
| Writing | |
| Payment value, $ (%) | 797,929 (4.5) |
| Contracts, n (%) | 1086 (5.0) |
| Other | |
| Payment value, $ (%) | 397,659 (2.2) |
| Contracts, n (%) | 459 (2.1) |